title: Effects of oral albuterol on serum lipids and carbohydrate metabolism in healthy men.
abstract: beta(2)-Selective adrenergic agonists are used in the management of bronchial asthma and preterm labor. Due to their ability to increase muscle strength and size in animal models, new applications for these agents are also being explored for neuromuscular disorders and in rehabilitation. However, the effects of long-term beta(2)-agonist administration on lipoprotein and carbohydrate metabolism are incompletely understood. This investigation evaluated the effects of a beta(2)-agonist, albuterol, on serum lipids and carbohydrate homeostasis in eight healthy nonsmoking men aged 24 to 61 years. Collection of fasting blood samples was completed in duplicate on separate days at baseline, during 14 days of oral albuterol administration (Proventil Repetabs, 8 mg twice daily; Schering Pharmaceuticals, Kenilworth, NJ) and during a 7-day washout period. Carbohydrate homeostasis was evaluated using the minimal model technique at the end of the baseline and albuterol periods. Fasting glucose and insulin, intravenous glucose tolerance, acute insulin response to intravenous glucose (AIRg), insulin sensitivity (Si), and glucose effectiveness (Sg) were not significantly changed during albuterol administration. Significant alterations (P < or = .02) were observed in total cholesterol ([TC] -9.1% +/- 2.5%), low-density lipoprotein cholesterol ([LDL-C] -15.0% +/- 2.9%), and high-density lipoprotein cholesterol ([HDL-C] +10.4% +/- 3.2%) concentrations, as well as the TC/HDL-C (-17.4% +/- 2.6%) and LDL-C/HDL-C (-22.9% +/- 2.4%) ratios. During washout, TC and LDL-C returned to baseline levels, whereas HDL-C remained elevated by 5.8% +/- 2.4% (P < .05). Thus, albuterol administration was associated with favorable changes in the serum lipid profile without marked impairment of glucose tolerance or its physiologic determinants.
authors.affiliation: Edward Hines, Jr, Veterans Affairs Hospital, Hines, IL, USA.
authors.forename: K C
authors.initials: KC
authors.lastname: Maki
authors.forename: M S
authors.initials: MS
authors.lastname: Skorodin
authors.forename: J H
authors.initials: JH
authors.lastname: Jessen
authors.forename: F
authors.initials: F
authors.lastname: Laghi
mesh_terms: D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000886:Anthropometry; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D050260:Carbohydrate Metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008274:Magnesium / Q000097:blood; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011188:Potassium / Q000097:blood; D012016:Reference Values; D012129:Respiratory Function Tests; D014527:Uric Acid / Q000097:blood
chemical_list: D000318:Adrenergic beta-Agonists; D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D014527:Uric Acid; D008274:Magnesium; D000420:Albuterol; D011188:Potassium